This activity is jointly provided by
STATEMENT OF NEED
Chemotherapy-induced nausea and vomiting (CINV) is highly prevalent, occurring in up to 80% of patients receiving chemotherapy. In one study of 151 cancer patients from 10 community cancer centers who were scheduled for a new chemotherapy regimen, 67% experienced either acute or delayed CINV during their first cycle (Cohen et al, 2007). Delayed CINV was more common than acute CINV (59% vs 36%), although many patients experienced both types. When uncontrolled, CINV is reported by patients to significantly impair quality of life and reduce daily functioning. Uncontrolled CINV can lead to severe clinical conditions, including electrolyte imbalance, dehydration, and malnutrition, which may compromise the ability of patients to respond to cancer treatment. Furthermore, the costs associated with uncontrolled CINV can be significant. A retrospective analysis of 19,139 patients showed that the average expense for patients who needed hospital care for CINV was $5,299 (US) versus $731 for those who did not (Burke et al, 2011).
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the management of chemotherapy-induced nausea and vomiting in patients with cancer.
Upon completion of this activity, participants should be able to:
- Assess patient risk factors and nonchemotherapy causes of CINV
- Differentiate guideline recommendations for the management of acute, delayed, breakthrough, and refractory CINV
- Evaluate emerging data on novel antiemetic strategies and their application in clinical practice
Lee Schwartzberg, MD, FACP (Chairperson)
University of Tennessee West Cancer Center
Rudolph M. Navari, MD, PhD, FACP
Professor of Medicine
University of Alabama Birmingham School of Medicine
Charles L. Loprinzi, MD
Professor of Oncology
Mayo Clinic College of Medicine
Mark G. Kris, MD
Professor of Medicine
Weill Cornell Medical College
There is no fee to participate in or claim CME credit for this activity.
Please note that Global Education Group and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group and i3 Health. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Ashley Marostica, RN, MSN: Nothing to disclose
Andrea Funk: Nothing to disclose
Laura Gilsdorf: Nothing to disclose
Melissa L. Cutrona: Nothing to disclose
Michael Bramwell: Nothing to disclose
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Lee Schwartzberg, MD, FACP discloses that he has served as a consultant/independent contractor for: Eisai, Helsinn, Heron, Merck and Tesaro. He has received grant/research support from Helsinn.
Rudolph M. Navari, MD, PhD, FACP has no relevant financial relationships to disclose.
Charles L. Loprinzi, MD discloses that he has served as a consultant/independent contractor for Mandipharma. He has received grant/research support from Bristol-Myers Squibb.
Mark G. Kris, MD discloses that he has served as a consultant/independent contractor for AstraZeneca.
UNAPPROVED USE DISCLOSURE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and i3 Health do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
This activity is supported by an educational grant from TESARO.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.